Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Thrombin Market by Dosage form (Spray kits, Powder form, Solution form, Patch, Others), by Product Type (Alpha-thrombin, Beta thrombin, Gamma-thrombin) and by End user (Diagnostic and clinics, Hospitals, Ambulatory surgical centers, Academic and research institutes): Global Opportunity Analysis and Industry Forecast, 2023-2032

A08396

Pages: NA

Charts: NA

Tables: NA

Thrombin Market Overview

Thrombin is defined as a naturally occurring enzyme which converts fibrinogen into fibrin and results into clot formation. Thrombin has been invented from different sources and called as a hemostatic aid. Thrombin was found from bovine plasma and now thrombin is derived from the recombinant sources and human plasma. Thrombin is used at the end of the coagulation cascade and it is used as clotting factor. Thrombin is also used in the prothrombin, formation of antibodies against thrombin, cardiolipin and factor V. Thrombin is also used during operation near larger vessels is conducted to prevent disseminated intravascular coagulation (DIC) and death.
In adults, the ordinary blood level of anti-thrombin movement has been estimated to be around 1.1 units/mL. Infant levels of thrombin consistently increment after birth to arrive at typical grown-up levels from a degree of around 0.5 units/mL 1 day after birth to a degree of around 0.9 units/mL following a half year of life. Thrombin collaborates with thrombomodulin to increase the strength of the fibrin.

COVID-19 Scenario analysis on Thrombin Market

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

Increase in number of cases for acquired blood coagulating diseases such as hemophilia, Von Willebrand disease are the factors contributing to the market growth. Also, increasing use of thrombin by the patients will drive the market growth. Increase in the number of accidents and injuries are the factors influencing the thrombin market growth. According to WHO report, it is found that 1.35 million individuals die every year, because of street car accidents and 20-50 million additional individuals endure non-lethal wounds, with many acquiring a handicap because of their physical issue this would further contribute to the thrombin market growth.

Thrombin is used in safer hemostatic condition and post-operative complications which would drive market growth. The only source of thrombin is human plasma and due to its risk of transmitting infectious agents which is restraining market growth.

Thrombin plays a significant role in the surgeries around the world and is used in the careful hemostasis, which is driving the thrombin market growth. Human thrombin was replaced with bovine thrombin because of its expanded productivity in surgeries.

Key benefits of the report:

  • This study presents the analytical depiction of the global thrombin market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints and opportunities along with detailed analysis of the global thrombin market share.
  • The current market is quantitatively analyzed to highlight the growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the thrombin market.
  • The report provides a detailed global thrombin market analysis based on competitive intensity and how the competition will take shape in coming years. 

Questions answered in the thrombin market research report:

  • Who are the leading market players active in the thrombin market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What can be the challenges for the thrombin market in future?
  • What are the projections for the future that will help in taking further strategic steps?

 Key Market Segments

  • By Dosage form
    • Spray kits
    • Powder form
    • Solution form
    • Patch
    • Others
  • By Product Type
    • Alpha-thrombin
    • Beta thrombin
    • Gamma-thrombin
  • By End user
    • Diagnostic and clinics
    • Hospitals
    • Ambulatory surgical centers
    • Academic and research institutes
  • By Region
    • North America
      • US
      • Canada
    • Europe
      • Germany
      • UK
      • France
      • rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • rest of Asia-Pacific
    • Latin America
      • Brazil
      • Mexico
      • rest of LATAM
    • The Middle East
    • Africa

 
Key Market Players

  • Hualan Biological
  • Octapharma
  • Pfizer
  • Omrix Biopharmaceuticals Ltd.
  • CSL
  • Haematologic Technologies Inc.
  • Shanghai RAAS
  • Grifols
  • GE Healthcare
  • Bayer
  • Baxter

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: THROMBIN MARKET, BY DOSAGE FORM

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Dosage Form

    • 4.2. Spray Kits

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Powder Form

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Solution Form

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Patch

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: THROMBIN MARKET, BY PRODUCT TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Product Type

    • 5.2. Alpha-thrombin

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Beta Thrombin

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Gamma-thrombin

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: THROMBIN MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Diagnostic And Clinics

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Hospitals

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Ambulatory Surgical Centers

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Academic And Research Institutes

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: THROMBIN MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Dosage Form

      • 7.2.3. Market Size and Forecast, By Product Type

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Thrombin Market

        • 7.2.6.1. Market Size and Forecast, By Dosage Form
        • 7.2.6.2. Market Size and Forecast, By Product Type
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Thrombin Market

        • 7.2.7.1. Market Size and Forecast, By Dosage Form
        • 7.2.7.2. Market Size and Forecast, By Product Type
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Thrombin Market

        • 7.2.8.1. Market Size and Forecast, By Dosage Form
        • 7.2.8.2. Market Size and Forecast, By Product Type
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Dosage Form

      • 7.3.3. Market Size and Forecast, By Product Type

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Thrombin Market

        • 7.3.6.1. Market Size and Forecast, By Dosage Form
        • 7.3.6.2. Market Size and Forecast, By Product Type
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Thrombin Market

        • 7.3.7.1. Market Size and Forecast, By Dosage Form
        • 7.3.7.2. Market Size and Forecast, By Product Type
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Thrombin Market

        • 7.3.8.1. Market Size and Forecast, By Dosage Form
        • 7.3.8.2. Market Size and Forecast, By Product Type
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Thrombin Market

        • 7.3.9.1. Market Size and Forecast, By Dosage Form
        • 7.3.9.2. Market Size and Forecast, By Product Type
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Thrombin Market

        • 7.3.10.1. Market Size and Forecast, By Dosage Form
        • 7.3.10.2. Market Size and Forecast, By Product Type
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Thrombin Market

        • 7.3.11.1. Market Size and Forecast, By Dosage Form
        • 7.3.11.2. Market Size and Forecast, By Product Type
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Thrombin Market

        • 7.3.12.1. Market Size and Forecast, By Dosage Form
        • 7.3.12.2. Market Size and Forecast, By Product Type
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Dosage Form

      • 7.4.3. Market Size and Forecast, By Product Type

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Thrombin Market

        • 7.4.6.1. Market Size and Forecast, By Dosage Form
        • 7.4.6.2. Market Size and Forecast, By Product Type
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Thrombin Market

        • 7.4.7.1. Market Size and Forecast, By Dosage Form
        • 7.4.7.2. Market Size and Forecast, By Product Type
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Thrombin Market

        • 7.4.8.1. Market Size and Forecast, By Dosage Form
        • 7.4.8.2. Market Size and Forecast, By Product Type
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Thrombin Market

        • 7.4.9.1. Market Size and Forecast, By Dosage Form
        • 7.4.9.2. Market Size and Forecast, By Product Type
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Thrombin Market

        • 7.4.10.1. Market Size and Forecast, By Dosage Form
        • 7.4.10.2. Market Size and Forecast, By Product Type
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Thrombin Market

        • 7.4.11.1. Market Size and Forecast, By Dosage Form
        • 7.4.11.2. Market Size and Forecast, By Product Type
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Thrombin Market

        • 7.4.12.1. Market Size and Forecast, By Dosage Form
        • 7.4.12.2. Market Size and Forecast, By Product Type
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Thrombin Market

        • 7.4.13.1. Market Size and Forecast, By Dosage Form
        • 7.4.13.2. Market Size and Forecast, By Product Type
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Thrombin Market

        • 7.4.14.1. Market Size and Forecast, By Dosage Form
        • 7.4.14.2. Market Size and Forecast, By Product Type
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Dosage Form

      • 7.5.3. Market Size and Forecast, By Product Type

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Thrombin Market

        • 7.5.6.1. Market Size and Forecast, By Dosage Form
        • 7.5.6.2. Market Size and Forecast, By Product Type
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Thrombin Market

        • 7.5.7.1. Market Size and Forecast, By Dosage Form
        • 7.5.7.2. Market Size and Forecast, By Product Type
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Thrombin Market

        • 7.5.8.1. Market Size and Forecast, By Dosage Form
        • 7.5.8.2. Market Size and Forecast, By Product Type
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Thrombin Market

        • 7.5.9.1. Market Size and Forecast, By Dosage Form
        • 7.5.9.2. Market Size and Forecast, By Product Type
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Thrombin Market

        • 7.5.10.1. Market Size and Forecast, By Dosage Form
        • 7.5.10.2. Market Size and Forecast, By Product Type
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Thrombin Market

        • 7.5.11.1. Market Size and Forecast, By Dosage Form
        • 7.5.11.2. Market Size and Forecast, By Product Type
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Baxter

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Shanghai RAAS

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Bayer

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Omrix Biopharmaceuticals Ltd.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. CSL

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Octapharma

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Grifols

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Pfizer

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Haematologic Technologies Inc.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. GE Healthcare

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Hualan Biological

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL THROMBIN MARKET, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL THROMBIN MARKET FOR SPRAY KITS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL THROMBIN MARKET FOR POWDER FORM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL THROMBIN MARKET FOR SOLUTION FORM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL THROMBIN MARKET FOR PATCH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL THROMBIN MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL THROMBIN MARKET, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL THROMBIN MARKET FOR ALPHA-THROMBIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL THROMBIN MARKET FOR BETA THROMBIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL THROMBIN MARKET FOR GAMMA-THROMBIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL THROMBIN MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL THROMBIN MARKET FOR DIAGNOSTIC AND CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL THROMBIN MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL THROMBIN MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL THROMBIN MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL THROMBIN MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA THROMBIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 20. NORTH AMERICA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. U.S. THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 22. U.S. THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 23. U.S. THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. CANADA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 25. CANADA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 26. CANADA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 29. MEXICO THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE THROMBIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 33. EUROPE THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 36. FRANCE THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 39. GERMANY THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. ITALY THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 41. ITALY THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 42. ITALY THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 45. SPAIN THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. UK THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 47. UK THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 48. UK THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 51. RUSSIA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 54. REST OF EUROPE THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC THROMBIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 58. ASIA-PACIFIC THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. CHINA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 60. CHINA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 61. CHINA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 64. JAPAN THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. INDIA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 66. INDIA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 67. INDIA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 70. SOUTH KOREA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 73. AUSTRALIA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 76. THAILAND THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 79. MALAYSIA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 82. INDONESIA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA THROMBIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 89. LAMEA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 92. BRAZIL THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 95. SOUTH AFRICA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 98. SAUDI ARABIA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 99. UAE THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 100. UAE THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 101. UAE THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 104. ARGENTINA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA THROMBIN, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA THROMBIN, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 107. REST OF LAMEA THROMBIN, BY END USER, 2025-2033 ($MILLION)
  • TABLE 108. BAXTER: KEY EXECUTIVES
  • TABLE 109. BAXTER: COMPANY SNAPSHOT
  • TABLE 110. BAXTER: OPERATING SEGMENTS
  • TABLE 111. BAXTER: PRODUCT PORTFOLIO
  • TABLE 112. BAXTER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. SHANGHAI RAAS: KEY EXECUTIVES
  • TABLE 114. SHANGHAI RAAS: COMPANY SNAPSHOT
  • TABLE 115. SHANGHAI RAAS: OPERATING SEGMENTS
  • TABLE 116. SHANGHAI RAAS: PRODUCT PORTFOLIO
  • TABLE 117. SHANGHAI RAAS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. BAYER: KEY EXECUTIVES
  • TABLE 119. BAYER: COMPANY SNAPSHOT
  • TABLE 120. BAYER: OPERATING SEGMENTS
  • TABLE 121. BAYER: PRODUCT PORTFOLIO
  • TABLE 122. BAYER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 123. OMRIX BIOPHARMACEUTICALS LTD.: KEY EXECUTIVES
  • TABLE 124. OMRIX BIOPHARMACEUTICALS LTD.: COMPANY SNAPSHOT
  • TABLE 125. OMRIX BIOPHARMACEUTICALS LTD.: OPERATING SEGMENTS
  • TABLE 126. OMRIX BIOPHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
  • TABLE 127. OMRIX BIOPHARMACEUTICALS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128. CSL: KEY EXECUTIVES
  • TABLE 129. CSL: COMPANY SNAPSHOT
  • TABLE 130. CSL: OPERATING SEGMENTS
  • TABLE 131. CSL: PRODUCT PORTFOLIO
  • TABLE 132. CSL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 133. OCTAPHARMA: KEY EXECUTIVES
  • TABLE 134. OCTAPHARMA: COMPANY SNAPSHOT
  • TABLE 135. OCTAPHARMA: OPERATING SEGMENTS
  • TABLE 136. OCTAPHARMA: PRODUCT PORTFOLIO
  • TABLE 137. OCTAPHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 138. GRIFOLS: KEY EXECUTIVES
  • TABLE 139. GRIFOLS: COMPANY SNAPSHOT
  • TABLE 140. GRIFOLS: OPERATING SEGMENTS
  • TABLE 141. GRIFOLS: PRODUCT PORTFOLIO
  • TABLE 142. GRIFOLS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. PFIZER: KEY EXECUTIVES
  • TABLE 144. PFIZER: COMPANY SNAPSHOT
  • TABLE 145. PFIZER: OPERATING SEGMENTS
  • TABLE 146. PFIZER: PRODUCT PORTFOLIO
  • TABLE 147. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. HAEMATOLOGIC TECHNOLOGIES INC.: KEY EXECUTIVES
  • TABLE 149. HAEMATOLOGIC TECHNOLOGIES INC.: COMPANY SNAPSHOT
  • TABLE 150. HAEMATOLOGIC TECHNOLOGIES INC.: OPERATING SEGMENTS
  • TABLE 151. HAEMATOLOGIC TECHNOLOGIES INC.: PRODUCT PORTFOLIO
  • TABLE 152. HAEMATOLOGIC TECHNOLOGIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. GE HEALTHCARE: KEY EXECUTIVES
  • TABLE 154. GE HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 155. GE HEALTHCARE: OPERATING SEGMENTS
  • TABLE 156. GE HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 157. GE HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 158. HUALAN BIOLOGICAL: KEY EXECUTIVES
  • TABLE 159. HUALAN BIOLOGICAL: COMPANY SNAPSHOT
  • TABLE 160. HUALAN BIOLOGICAL: OPERATING SEGMENTS
  • TABLE 161. HUALAN BIOLOGICAL: PRODUCT PORTFOLIO
  • TABLE 162. HUALAN BIOLOGICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL THROMBIN MARKET SEGMENTATION
  • FIGURE 2. GLOBAL THROMBIN MARKET
  • FIGURE 3. SEGMENTATION THROMBIN MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN THROMBIN MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALTHROMBIN MARKET
  • FIGURE 11. THROMBIN MARKET SEGMENTATION, BY BY DOSAGE FORM
  • FIGURE 12. THROMBIN MARKET FOR SPRAY KITS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. THROMBIN MARKET FOR POWDER FORM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. THROMBIN MARKET FOR SOLUTION FORM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. THROMBIN MARKET FOR PATCH, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. THROMBIN MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. THROMBIN MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 18. THROMBIN MARKET FOR ALPHA-THROMBIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. THROMBIN MARKET FOR BETA THROMBIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. THROMBIN MARKET FOR GAMMA-THROMBIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. THROMBIN MARKET SEGMENTATION, BY BY END USER
  • FIGURE 22. THROMBIN MARKET FOR DIAGNOSTIC AND CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. THROMBIN MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. THROMBIN MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. THROMBIN MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: THROMBIN MARKET
  • FIGURE 32. TOP PLAYER POSITIONING, 2024
  • FIGURE 33. BAXTER: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. BAXTER: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. BAXTER: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. SHANGHAI RAAS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. SHANGHAI RAAS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. SHANGHAI RAAS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. BAYER: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. BAYER: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. BAYER: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. OMRIX BIOPHARMACEUTICALS LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. OMRIX BIOPHARMACEUTICALS LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. OMRIX BIOPHARMACEUTICALS LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. CSL: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. CSL: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. CSL: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. OCTAPHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. OCTAPHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. OCTAPHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. GRIFOLS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. GRIFOLS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. GRIFOLS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. PFIZER: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. PFIZER: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. PFIZER: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. HAEMATOLOGIC TECHNOLOGIES INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. HAEMATOLOGIC TECHNOLOGIES INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. HAEMATOLOGIC TECHNOLOGIES INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 60. GE HEALTHCARE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 61. GE HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 62. GE HEALTHCARE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 63. HUALAN BIOLOGICAL: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 64. HUALAN BIOLOGICAL: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 65. HUALAN BIOLOGICAL: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Thrombin Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved